In the era of immunotherapy, response rate alone fails to predict true patient benefit

Regulators must adapt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Richard M. Goldberg, MD
Professor emeritus, Director emeritus, West Virginia University Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 
A study from researchers at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute identifies a potential way to make colorectal cancer more responsive to retinoids, compounds related to vitamin A that can help regulate how cells grow and mature. The article “Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: Basis for new drug combinations in oncology,” 
Richard M. Goldberg, MD
Professor emeritus, Director emeritus, West Virginia University Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login